Woodmont Investment Counsel LLC Has $15.53 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Woodmont Investment Counsel LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,629 shares of the company's stock after purchasing an additional 3,917 shares during the period. Johnson & Johnson makes up 1.1% of Woodmont Investment Counsel LLC's portfolio, making the stock its 22nd biggest position. Woodmont Investment Counsel LLC's holdings in Johnson & Johnson were worth $15,527,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Lantz Financial LLC increased its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $453,000. Horan Securities Inc. grew its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after purchasing an additional 90 shares during the last quarter. State of Wyoming grew its position in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC grew its position in shares of Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.0%

JNJ traded up $1.54 during trading on Monday, reaching $151.33. 7,269,653 shares of the company's stock were exchanged, compared to its average volume of 7,990,923. The company's fifty day moving average price is $154.07 and its 200-day moving average price is $153.68. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The firm has a market capitalization of $364.11 billion, a PE ratio of 16.83, a P/E/G ratio of 2.27 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, June 5th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.